# The Ensign Group, Inc. (ENSG)

> Source: Nexqual · https://nexqual.com/ENSG · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, The Ensign Group, Inc. (ENSG), nexqual.com/ENSG" · informational, not investment advice.

**Price:** USD 178.35 (+2.88% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 173.35 · day 172.12–178.63 · 52w 141.58–218 · market cap $10.4B · NMS

## Key facts
- 1 of 80 tracked superinvestors hold ENSG (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 220 (range 207–230).
- Total return with dividends: 1Y -3.6% vs S&P 500 +14.9%; 5Y +149.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 1.97, revenue estimate $1.51B.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold ENSG. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.02% | $10.4M | New position |

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 220 (low 207, high 230).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-30 | Truist Securities | Target raised | Hold | $202 → $207 |
| 2026-07-14 | Truist Securities | Target lowered | Hold | $215 → $202 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -3.6% | +149.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -3.7% | +20.0% |
| Volatility (annualized) | 27.9% | 24.0% |
| Max drawdown | -31.8% (Mar 2026→Jun 2026) | -30.2% (Feb 2026→Jun 2026) |

## Peers (Medical Care Facilities)
UHS (Universal Health Services, Inc.) USD 188.13 +2.88% · FMS (Fresenius Medical Care AG) USD 22.23 +3.11% · DVA (DaVita Inc.) USD 186.1 +5.25% · EHC (Encompass Health Corporation) USD 126.01 +4.60% · PACS (PACS Group, Inc.) USD 47.5 +1.58% · CHE (Chemed Corp) USD 520.15 +1.72%

## More
Full page: https://nexqual.com/ENSG · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name ENSG in their own reports (relationship from ENSG's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Pennant Group, Inc. (PNTG) | 10-K 2026-02-26 | "Pennant and Ensign continue to partner in the provision of services along the healthcare continuum." |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.97 | $1.90 | +3.5% | $1.51B | 5 |
| Next quarter (ends 2026-12-31) | $2.07 | $1.96 | +5.5% | $1.57B | 5 |
| Current fiscal year (ends 2026-12-31) | $7.81 | $7.56 | +3.4% | $5.90B | 5 |
| Next fiscal year (ends 2027-12-31) | $8.59 | $8.33 | +3.1% | $6.57B | 5 |